AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01362374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide will be administered orally at a dose level of 160 mg once daily continuously as per schedule defined in respective arm until disease progression or unacceptable toxicity.
Study NCT01362374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Ipatasertib will be administered orally (in escalating doses during Stage 1 followed by at a dose decided during Stage 1) as per schedule defined in the respective arms.
Study NCT02764151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06840003
Description: Daily Oral PF-06840003
Study NCT00791544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE1642
Description: intravenous infusion
Study NCT00791544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: oral intake
Study NCT01362374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin at a dose level of 400 mg/m\^2 as IV infusion over 2 hrs will be administered on Day 1 of each 14-day cycle until disease progression or unacceptable toxicity.
Study NCT01362374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin at a dose level of 85 mg/m\^2 as IV infusion over 2 hours will be administered on Day 1 of each 14-day cycle until disease progression or unacceptable toxicity.
Study NCT01362374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel at a dose of 90 mg/m\^2 as IV infusion over 1 hr will be administered on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
Study NCT00456131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Eating Behaviors Training
Description: The intervention group (other group is a control without any intervention) involves 6 one-hour group sessions teaching healthy eating habits and weight gain prevention tools.
Study NCT00380250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Study NCT00380250 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03022344 — intervention group
Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: Cardiac CT
Study NCT02657382 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart Rate Variability (HRV) Biofeedback (BF)
Description: Heart Rate Variability (HRV) biofeedback involves deep breathing, mindfulness (focusing on one's emotions and thoughts) and cognitive therapy (identifying and changing unhelpful or inaccurate thinking and distressing emotional responses). It is a 6-week training with one hour sessions with a certified biofeedback coach once per week. A handheld personal stress reliever device will be provided to the patients to practice at home for 20 minutes a day.
Study NCT02657382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental Stress Protocol
Description: Mental stress will consist of a 3-min math serial subtraction paradigm.The participants will be asked to serially subtract 7 from number specified by the researcher. For participants who have difficulty with this task, easier serial subtraction will be provided for. Throughout the task, to increase stressfulness and titrate difficulty, the participant will be prompted for faster performance and the starting number from which they were subtracting will be periodically changed. Finally, to add an evaluation component, participants will be given negative feedback during the test.
Study NCT03305198 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Capillary blood sampling from the earlobe
Description: Sample at rest before the walking test Sample at rest 3 minutes after the end of the walking period
Study NCT03120819 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Oncologist Recommendation
Description: Patients in this arm receive a 2-3 minute verbal recommendation about exercise from their treating oncologist
Study NCT03120819 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oncologist Recommendation + DVD
Description: Patients in this arm receive a 2-3 minute verbal recommendation about exercise from their treating oncologist and then be sent an instructional exercise DVD to follow at their home three times per week for eight weeks
Study NCT04459572 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: suPAR
Description: Soluble Urokinase Plasminogen Activator Receptor (suPAR)
Study NCT04201314 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: InnoSlim®
Description: Subjects take 2 capsules before breakfast and 3 capsules before dinner of similar appearance per day for 6 weeks of a stage.
Study NCT01344044 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BCI
Description: 24 half-hour sessions over 8 weeks, i.e. 3 sessions per week, followed by 3 once-monthly boosters.
Study NCT01344044 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: BCI
Description: 24 half-hour sessions over 8 weeks, i.e. 3 sessions per week, followed by 3 once-monthly boosters.
Study NCT00733772 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: flaxseed
Description: 30 grams/day of flaxseed for 12 weeks
Study NCT00733772 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health lifestyle counseling
Description: Health lifestyle counseling accroding to AHA reccommendation
Study NCT04201314 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: InnoSlim®
Description: Subjects take 2 capsules before breakfast and 3 capsules before dinner of similar appearance per day for 6 weeks of a stage.
Study NCT04201314 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects take 2 starch capsules before breakfast and 3 starch capsules before dinner of similar appearance per day for 6 weeks of a stage.
Study NCT04201314 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects take 2 starch capsules before breakfast and 3 starch capsules before dinner of similar appearance per day for 6 weeks of a stage.
Study NCT00791544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: oral intake
Study NCT03197181 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: Participants receive anodal or sham transcranial direct current stimulation while performing effort-based decision tasks.
Study NCT03197181 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: Participants receive anodal or sham transcranial direct current stimulation while performing effort-based decision tasks.
Study NCT00733772 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Health lifestyle counseling
Description: Health lifestyle counseling accroding to AHA reccommendation
Study NCT02857192 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Study NCT02857192 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Blood samples
Study NCT04261959 — intervention group
Intervention type: OTHER
Intervention: myoActivation
Description: myoActivation is a novel, structured assessment and non-pharmacological therapeutic approach to both diagnosis and treatment of chronic myofascial pain. A detailed history of the timeline of lifetime trauma combined with a quick, structured and reproducible set of posture and movement tests help to easily identify myofascial components of chronic pain. The therapeutic component is delivered utilizing a needling technique, or myofascial release, focused to active myofascial trigger points, fascia in tension and tethered scars.
Study NCT04261959 — intervention group
Intervention type: OTHER
Intervention: Physiotherapy
Description: Physiotherapy aims to reduce a patient's pain experience and increase their physical function through physical examination, diagnosis, prognosis, physical intervention, rehabilitation and education (including pain neurophysiology education).
Study NCT00712218 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No Lymphadenectomy (LNE)
Description: No lymphadenectomy is performed in patients of the control group
Study NCT00712218 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphadenectomy (LNE)
Description: Patients allocated to the lymphadenectomy group undergo systematic lymphadenectomy in addition to surgery for complete resection. Complete mobilization of the colon by resection of the paracolic gutters is necessary for the preparation of the lymphadenectomy. Afterwards the peritoneum has to be opened until the Treitzsche's Band for visualization of the renal vein. Systematic pelvic and para-aortic lymphadenectomy is based on anatomical studies and defined according to a recently published single centre series as systematic resection of lymph nodes in the following regions \[24, \].
Study NCT04376957 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multinational Association of Supportive Care in Cancer Oral agent Teaching Tool
Description: This tool was developed by an expert panel of oncology nurses and was further revised following external review of health care providers world-wide. This tools involves four key modules 1) patient's baseline knowledge, 2) patient education of oral cancer drugs 4) patient education tailored to a specific cancer drug 4) evaluation of the educational material.~It was originally studied in 30 patients with lung cancer and was shown to be feasible with acceptable knowledge retention. Similarly, in a single center cohort study of general oncology patients, medication adherence self-efficacy appeared to improve with MOATT. The MOATT interventional tool incorporates key components of patient education and also has the advantage of being a potentially feasible tool that can be incorporated into future routine clinical practise.
Study NCT04376957 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care consisting of standard counselling
Description: Consists of instructions and information on the regimen, common side effects, symptom management, medication safety and how to contact a clinician for any problems encountered.
Study NCT04421859 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EyeCU Mobile Application
Description: Augmented reality glaucoma education mobile phone application
Study NCT04173195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comfort Talk
Description: A short and brief conversation based on the principles of clinical hypnosis.
Study NCT03346265 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment A combined exercise program and gait training with sensory cues
Description: Treatment A consisted in a combined exercise program of 40 min duration RMP
Study NCT03346265 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment B Conventional physiotherapy
Description: Conventional physiotherapy was composed of 4 sections of exercises, chiefly oriented to different body structures appropriate to movement (International Classification of Functioning, Disability and Health code)
Study NCT02725112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin ER
Description: A: Pregabalin ER tablet formulation, Target release rate, 1 x 330 mg, Oral.
Study NCT02725112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin ER
Description: B: Pregabalin ER tablet formulation, Slow release rate, 1 x 330 mg, Oral.
Study NCT02725112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin ER
Description: C: Pregabalin ER tablet formulation, Fast release rate, 1 x 330 mg, Oral.
Study NCT02725112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin ER
Description: D: Pregabalin IR capsule formulation, 1 x 300 mg, Oral.
Study NCT02725112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin ER
Description: E: Pregabalin ER tablet formulation, Target release rate, 1 x 82.5 mg, Oral.
Study NCT02725112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin ER
Description: F: Pregabalin ER tablet formulation, Aberrant fast release rate, 1 x 330 mg, Oral.
Study NCT02688088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug Cocktail
Description: Administered orally
Study NCT02688088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug Cocktail
Description: Administered orally
Study NCT02688088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally
Study NCT01839019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-102
Description: Single dose escalation
Study NCT01839019 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ODM-102
Description: Single dose escalation
Study NCT05393414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid based protocol
Description: Use of combination of drug dosage frequency and duration of morphine injection with percocet oral as standard postoperative pain control for up to 72 hours as requested by each patient
Study NCT05393414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid sparing protocol
Description: Use of combination of drug dosage frequency and duration of ketorolac injection with acetaminophen oral as standard postoperative pain control for up to 72 hours as requested by each patient
Study NCT00366028 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Organization Model
Description: The organizational model contains three components: leadership support, a multidisciplinary redesign team, and management structures and processes to link the two.
Study NCT04577118 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: iotaSOFT Insertion System
Description: Enrolled subjects undergoing cochlear implant surgery will have the iotaSOFT Insertion System used by the surgeon to assist with implantation of the implant electrode array during the procedure.
Study NCT00366028 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Data Feedback Model
Description: The research team will periodically interview the facilities and provide them with reported hand hygiene data.
Study NCT01246479 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood draw
Description: blood draw at Month 12, Month 24 and Month 36.
Study NCT00876005 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen by mask
Description: Postoperatively, an aerosol face mask is used to deliver oxygen at 80%
Study NCT00876005 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen by mask
Description: Postoperatively, an aerosol face mask is used to deliver oxygen at 30%
Study NCT03156738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-2990
Description: Subjects will receive a single IV dose of MT-2990
Study NCT00782145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Study NCT00782145 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational intervention
Study NCT01246479 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: IC51 has given in the parent study IC51-322
Description: No more vaccinations in IC51-324 since this a study for long-term follow-up on safety and immunogenicity after vaccinations in parent study IC51-322.
Study NCT00782145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: informational intervention
Study NCT00782145 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: informational intervention
Study NCT00564330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: 20mg bid
Study NCT03172065 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Normal saline
Description: intravenous flluid
Study NCT00564330 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo bid
Study NCT03309527 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-aid Cognitive Behavior Therapy
Description: e-aid Cognitive Behavior Therapy
Study NCT03309527 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: e-aid Sleep Hygiene Education
Description: e-aid Sleep Hygiene Education
Study NCT00782145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: internet-based intervention
Study NCT00782145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Study NCT00782145 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Study NCT00782145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: study of socioeconomic and demographic variables
Study NCT00782145 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: study of socioeconomic and demographic variables
Study NCT00782145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey administration
Study NCT03147625 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHAPE Intervention
Description: SHAPE seeks to identify, equip and strengthen resources in elderly residing in elderly-only households. The content will be further developed according to the findings of an existing descriptive qualitative study, literature review and a multi-disciplinary expert panel review. The home visit will involve assessment, observation and evaluation of elderly' health status, lifestyle and home environment, followed by guidance on health-promoting behaviour and emphasis on strengthening inner health resources. This provides an individualized approach to enhance personal health skills. Group-based activity sessions are directed to facilitate group interaction among peers as well as equipping and enhancing external resources.
Study NCT02918253 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: targeted focal HDR brachytherapy
Study NCT02918253 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole-gland HDR Brachytherapy
Description: Control/Standard of Care
Study NCT03331835 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brodalumab
Description: Brodalumab is a recombinant fully human monoclonal immunoglobulin IgG2-antibody that binds with high affinity to human interleukin 17 receptor A (IL-17RA).~Blocking IL-17RA inhibits IL-17 cytokine-induced responses and results in reduced or normalised inflammation of the skin in subjects with psoriasis.
Study NCT03331835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fumaric acid esters
Description: Fumaric acid esters have been used to treat psoriasis since 1959. Systemic therapy with fumaric acid esters is based on an established dosing scheme with a gradual increase to improve tolerability, especially with regards to gastrointestinal side effects.
Study NCT00782145 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: survey administration
Study NCT00782145 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: psychosocial assessment and care
Study NCT00782145 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: psychosocial assessment and care
Study NCT00782145 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Study NCT00782145 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Study NCT00782145 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard follow-up care
Study NCT00782145 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard follow-up care
Study NCT01977508 — intervention group
Intervention type: DEVICE
Intervention: ePTFE vascular access grafts
Study NCT03761381 — intervention group
Intervention type: DEVICE
Intervention: Optical Coherence Tomography Angiography (OCTA) Imaging
Description: Optical coherence tomography is a non-invasive imaging technology that provides cross-sectional images of tissues in micron-scale resolution. The angiography component of this device allows for evaluation of blood vessel and blood flow changes in the eye. The Solix device with AngioVue software will be used to detect these blood vessel and flow changes as well as protein deposits in the retinal layers.
Study NCT00451646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMOF lipid and Intralipid
Description: 1-2 g, 5-7 days, 28 days
Study NCT00451646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SMOF lipid and Intralipid
Description: 1-2 g, 5-7 days, 28 days
Study NCT04169945 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonic instrumentation
Description: Full mouth root surface debridement
Study NCT03172065 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine
Description: anaesthetic adjuvants and pain killer medication.
Study NCT01952444 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETI-204
Description: A single IV infusion of 16 mg/kg ETI-204 over 90 minutes on Day 1
Study NCT01952444 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: ETI-204
Description: A single IV infusion of 16 mg/kg ETI-204 over 90 minutes on Day 1
Study NCT01952444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: A single IV Infusion of 400 mg Ciprofloxacin over 60 minutes immediately following the infusion of ETI-204 on Day 1, followed by oral Ciprofloxacin (750 mg every 12 hours) on Days 2-8, and a final oral dose on the morning of Day 9.